Бенрализумаб (MEDI-563)
Многоцентровое, открытое исследование продолжения терапии бенрализумабом (MEDI-563) для дальнейшей оценки его безопасности у взрослых пациентов с бронхиальной астмой, получающих комбинацию ингаляционных кортикостероидов и β2-агонистов длительного действия (MELTEMI)
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/304/2016-05-04/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); clinmarket. Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 20 чел. в стране «Россия».
- Центров в реестре: 7 в 6 городах. Список — ниже на странице.
- Плановая дата окончания (01.2021) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 5 · невключение: 16
Критерии включения
- Informed consent for study participation must be obtained prior to any study related procedures being performed and according to international guidelines and/or applicable European Union guidelines.
- Female and male patients who have completed at least 16 and not more than 40 weeks in Study D3250C00021.
- Women of childbearing potential (WOCBP) must agree to use an effective form of birth control throughout the study duration and for 16 weeks after the last dose of Investigational Product (IP)
- For WOCBP only: Have a negative urine pregnancy test prior to administration of IP at Visit 1.
- All male patients who are sexually active must agree to use a double barrier method of contraception (condom with spermicide) from the first dose of IP until 16 weeks after their last dose.
Критерии невключения
- Any disorder including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric or major physical impairment that is not stable in the opinion of the Investigator and could:
- Affect the safety of the patient throughout the study
- Influence the findings of the study or their interpretations
- Impede the patient's ability to complete the entire duration of study
- A helminth parasitic infection diagnosed during a predecessor study that has either required hospitalization, has not been treated, has been incompletely treated or has failed to respond to standard of care therapy
- Any clinically significant change in physical examination, vital signs, ECG, hematology, clinical chemistry, or urinalysis during the predecessor study which in the opinion of the investigator may put the patient at risk because of his/her participation in the study, or may influence the results of the study, or interfere with the patient's ability to complete the entire duration of the study
- Current malignancy or malignancy that developed during the predecessor study (subjects that had basal cell carcinoma, localized squamous cell carcinoma of the skin which was resected for cure, or in situ carcinoma of the cervix that has been treated/cured will not be excluded).
- Receipt of live attenuated vaccines within 30 days prior to initiation of treatment in this study, during the treatment period, and for 16 weeks (5 half-lives) after the last dose of the IP
- Receipt of immunoglobulin or blood products within 30 days prior to Visit 1
- Planned major surgical procedures during the conduct of the study
- Previous participation in the present study
- Concurrent enrolment in another drug-related interventional clinical trial
- AstraZeneca staff involved in the planning and/or conduct of the study
- Employees of the study center or any other individuals involved with the conduct of the study or immediate family members of such individuals
- Patients with important protocol deviations in the predecessor study at the discretion of the Sponsor
- Patients with ongoing serious adverse events (SAEs) from the prior study should not be enrolled into the this extension study until the SAE has resolved
Источник: ClinicalTrials.gov, NCT02808819 · запись обновлена в реестре 13 апреля 2021.
Дизайн и результаты
Что измеряют — первичные конечные точки (10), вторичных — 5
- Change From Baseline in Basophils, Full Analysis Set — From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
- Change From Baseline in Leukocytes, Full Analysis Set — From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
- Change From Baseline in Lymphocytes, Full Analysis Set — From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
- Change From Baseline in Neutrophils, Full Analysis Set — From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
- Change From Baseline in Monocytes, Full Analysis Set — From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
- Change From Baseline in Platelets, Full Analysis Set — From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
- Change From Baseline in Hematocrit, Full Analysis Set — From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
- Change From Baseline in Erythrocytes, Full Analysis Set — From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
- Change From Baseline in Hemoglobin, Full Analysis Set — From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
- Change From Baseline in Alanine Aminotransferase (ALT), Full Analysis Set — From Week 0 to Benralizumab is available in the local market or early discontinuation. Change from week 0 to the end of treatment period/early discontinuation is presented.
Цель исследования
The purpose of this study is to continue to characterize the safety profile of benralizumab administration and monitor the pharmacodynamic activity of the drug in those asthma patients who remain on treatment for at least 16 weeks and not more than 40 weeks in the predecessor study D3250C00021 (BORA, NCT02258542).
Области и заболевания
Где проходит
7 центров в 6 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 304 от 04.05.2016 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик, центры
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT02808819 Официальный реестр (США) · загружено 9 ноября 2026Цель
-
clinmarket · № 2938 Каталог исследований · загружено 1 октября 2026Статус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.